Emergent BioSolutions | EBS - Текущие обязательства





Текущие обязательства Изменить Дата
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Akebia Therapeutics USD 173.88M 10.95M 2026-03
ALKERMES USD 662.09M 62.59M 2026-06
Alnylam Pharmaceuticals USD 1.51B 163.04M 2026-06
Amarin USD 164.2M 15.45M 2026-06
ANI Pharmaceuticals USD 239.51M 38.6M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Coherus Biosciences USD 140.39M 231.91M 2025-12
Emergent BioSolutions USD 651.3M 12.7M 2023-12
Exelixis USD 370.98M 34.67M 2026-03
Glaxosmithkline GBP 22.43B 6.39B 2026-03
Heron Therapeutics USD 90.52M 5.58M 2026-03
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
Ironwood Pharmaceuticals USD 236.31M 5.91M 2026-03
Lexicon Pharmaceuticals USD 9.9M 10.97M 2026-03
Lonza CHF 3.57B 421M 2025-12
Merck USD 26.94B 1.38B 2026-03
Moderna USD 2.4B 408M 2026-03
Myriad Genetics USD 130.2M 3.6M 2026-03
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Pacira USD 108.79M 11.8M 2026-03
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 771.07M 152.54M 2026-06
Sanofi EUR 31.93B 1.92B 2026-06
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
United Therapeutics USD 599.1M 38.5M 2026-03
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12